5 results
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
12 May 23
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
8:03am
Officer, effective May 10, 2023, following his tenure as Executive Vice President & Chief Financial Officer of CinCor Pharma, Inc. (NASDAQ: CINC), where he
PRE 14A
IMPLQ
Impel Pharmaceuticals Inc
14 Apr 23
Preliminary proxy
4:11pm
of the directors attended fewer than 75% of the aggregate of the total number of meetings held by the Board of Directors during his or her tenure … and the total number of meetings held by all committees of the Board of Directors on which such director served during his or her tenure. The independent
DEF 14A
IMPLQ
Impel Pharmaceuticals Inc
26 Apr 22
Definitive proxy
4:16pm
or her tenure and the total number of meetings held by all committees of the Board of Directors on which such director served during his or her tenure … recommendations for nomination for reelection, the Nominating and Governance Committee considers director tenure. We value diversity on a company-wide basis
S-1
EX-10.9
IMPLQ
Impel Pharmaceuticals Inc
2 Apr 21
IPO registration
3:04pm
assumed and agreed to observe and perform any and all covenants and obligations of Landlord hereunder during the tenure of its interest in the Lease
- Prev
- 1
- Next